scholarly journals Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease

2015 ◽  
Vol 36 (11) ◽  
pp. 4421-4437 ◽  
Author(s):  
Rik Ossenkoppele ◽  
Brendan I. Cohn-Sheehy ◽  
Renaud La Joie ◽  
Jacob W. Vogel ◽  
Christiane Möller ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Stages

scholarly journals Can blood amyloid levels be used as a biomarker for Alzheimer’s disease?

2021 ◽  
Vol 7 (1) ◽  
pp. 17-25
Author(s):  
Yuan-Han Yang ◽  
Rocksy FV Situmeang ◽  
Paulus Anam Ong
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Outcomes ◽  
Tau Protein ◽  
Clinical Settings ◽  
Access Methods ◽  
Clinical Applicability ◽  
Clinical Stages ◽  
Aging Populations ◽  
Amyloid Aβ

Alzheimer’s disease (AD) increasingly affects society due to aging populations. Even at pre‐clinical stages, earlier and accurate diagnoses are essential for optimal AD management and improved clinical outcomes. Biomarkers such as beta‐amyloid (Aβ) or tau protein in cerebrospinal fluid (CSF) have been used as reliable markers to distinguish AD from non‐AD, and predicting clinical outcomes, to attain these goals. However, given CSF access methods’ invasiveness, these biomarkers are not used extensively in clinical settings. Blood Aβ has been proposed as an alternative biomarker since it is less invasive than CSF; however, sampling heterogeneity has limited its clinical applicability. In this review, we investigated blood Aβ as a biomarker in AD and explored how Aβ can be facilitated as a viable biomarker for successful AD management.

scholarly journals Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer’s Disease

2020 ◽  
pp. 1-13
Author(s):  
Roos J. Jutten ◽  
Sietske A.M. Sikkes ◽  
Rebecca E. Amariglio ◽  
Rachel F. Buckley ◽  
Michael J. Properzi ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Neuropsychological Tests ◽  
Clinical Stage ◽  
Word List ◽  
Time Interval ◽  
Cognitive Changes ◽  
Clinical Stages ◽  
Stage 1

Abstract Objective: Alzheimer’s disease (AD) studies are increasingly targeting earlier (pre)clinical populations, in which the expected degree of observable cognitive decline over a certain time interval is reduced as compared to the dementia stage. Consequently, endpoints to capture early cognitive changes require refinement. We aimed to determine the sensitivity to decline of widely applied neuropsychological tests at different clinical stages of AD as outlined in the National Institute on Aging – Alzheimer’s Association (NIA-AA) research framework. Method: Amyloid-positive individuals (as determined by positron emission tomography or cerebrospinal fluid) with longitudinal neuropsychological assessments available were included from four well-defined study cohorts and subsequently classified among the NIA-AA stages. For each stage, we investigated the sensitivity to decline of 17 individual neuropsychological tests using linear mixed models. Results: 1103 participants (age = 70.54 ± 8.7, 47% female) were included: n = 120 Stage 1, n = 206 Stage 2, n = 467 Stage 3 and n = 309 Stage 4. Neuropsychological tests were differentially sensitive to decline across stages. For example, Category Fluency captured significant 1-year decline as early as Stage 1 (β = −.58, p < .001). Word List Delayed Recall (β = −.22, p < .05) and Trail Making Test (β = 6.2, p < .05) became sensitive to 1-year decline in Stage 2, whereas the Mini-Mental State Examination did not capture 1-year decline until Stage 3 (β = −1.13, p < .001) and 4 (β = −2.23, p < .001). Conclusions: We demonstrated that commonly used neuropsychological tests differ in their ability to capture decline depending on clinical stage within the AD continuum (preclinical to dementia). This implies that stage-specific cognitive endpoints are needed to accurately assess disease progression and increase the chance of successful treatment evaluation in AD.

P2-288: Pyroglutamate and Full-Length Amyloid-B Concentrations in the Superior Frontal Cortex Across Clinical Stages of Alzheimer's Disease

2016 ◽  
Vol 12 ◽  
pp. P742-P743
Author(s):  
Eric E. Abrahamson ◽  
Gillian I. Kruszka ◽  
Zhiping Mi ◽  
William R. Paljug ◽  
Manik L. Debnath ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Frontal Cortex ◽  
Full Length ◽  
Clinical Stages ◽  
Superior Frontal Cortex

scholarly journals Dealing with uncertainty: biomarkers for the early detection of Alzheimer's disease

2012 ◽  
Vol 24 (10) ◽  
pp. 1533-1535 ◽  
Author(s):  
Robert Perneczky ◽  
Alexander Kurz
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Early Detection ◽  
Medial Temporal Lobe ◽  
Brain Disorders ◽  
Simple Set ◽  
Predominant Type ◽  
End Products ◽  
Clinical Stages ◽  
Asymptomatic Stage

In neuropsychiatric tradition, Alzheimer's disease (AD) is a clinical diagnosis that requires demonstration of a progressive memory-predominant type of dementia and exclusion of alternative causes. This simple set of criteria is neither sensitive for early clinical stages of AD since amnestic dementia only arises when the underlying neurodegeneration is fairly advanced, nor is it specific because it also occurs in other brain disorders involving the medial temporal lobe and cannot be easily distinguished from AD on clinical grounds. Efforts to identify AD before full-blown amnestic dementia develops, i.e. at a prodromal or even asymptomatic stage, and to treat the driving components of the pathology rather than its end products, are fueling the search for diagnostic indicators that unveil the neurodegeneration independently of its typical clinical manifestation. Such indicators are termed biomarkers in current technical parlance.

P1-050: Genome-wide association study in different clinical stages of Alzheimer's disease

2015 ◽  
Vol 11 (7S_Part_7) ◽  
pp. P357-P357 ◽  
Author(s):  
Jaeyoon Chung ◽  
Lindsay A. Farrer ◽  
Alzheimer's Disease Neuroimaging Initiative ◽  
Gyungah Jun
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Association Study ◽  
Genome Wide Association Study ◽  
Genome Wide Association ◽  
Genome Wide ◽  
Clinical Stages

scholarly journals Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease

2021 ◽  
Author(s):  
Julia Pfeil ◽  
Merle C. Hoenig ◽  
Elena Doering ◽  
Thilo van Eimeren ◽  
Alexander Drzezga ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Amyloid Burden ◽  
Regional Patterns ◽  
Clinical Stages

scholarly journals Empirically derived composite cognitive test scores to predict preclinical and clinical stages of Alzheimer’s disease

2021 ◽  
Vol 17 (S5) ◽  
Author(s):  
Rosita Shishegar ◽  
Tze Young Chai ◽  
Timothy Cox ◽  
Fiona Lamb ◽  
Joanne S. Robertson ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Test Scores ◽  
Cognitive Test ◽  
Clinical Stages
Sign in / Sign up

Export Citation Format

Share Document